中国抗体-B再涨超40% 公司配股筹资推进SM17的研发及临床项目以及潜在国际合作

智通财经
Jun 04, 2025

中国抗体-b(03681)昨日收涨逾30%,今日盘中再涨超40%。截至发稿,涨37%,报2.74港元,成交额1.31亿港元。消息面上,中国抗体今年4月份宣布,SM17在中重度特应性皮炎1b期临床试验中取得突破性结果,公司计划推进至2期试验。据悉,SM17作为一款全球首创的人源化igg4-κ单克隆抗体,其价值便在于能通过创新的作用机制,切实解决全球范围内包括AD、哮喘、特发性肺纤维化(IPF)及其他...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10